Drug Trial Radar · NCT00630968
S.K.A.T.E.: Safety of Keppra as Adjunctive Therapy in Epilepsy
Last checked: Nov 19, 2026Latest source record: Nov 15, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,541
Actual
Start
Aug 2000
Primary completion
Feb 2004
Study completion Feb 2004
Sponsor
- Lead sponsor
- UCB PharmaUCB
- Sponsor type
- Industry
- First posted
- Mar 7, 2008
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purposes of the study were to obtain further information about the optimal dose and the efficacy of Keppra in daily clinical practice, and to confirm the favorable safety and tolerability profiles of the drug observed during clinical development.
Conditions
- Epilepsy
Interventions
Levetiracetam (Keppra)Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage reduction in seizure frequency.Time frame: 16-week treatment period
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.